Jump to content

Imalumab

From Wikipedia, the free encyclopedia
Imalumab
Monoclonal antibody
Type?
Clinical data
Other namesBAX69
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2][3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[2] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[4]

A phase I/II trial in patients with malignant ascites was terminated in 2016.[4]

References

[edit]
  1. ^ Douillard P, Thiele M, Schinagl A, Halama N, Jaeger D, Yazji S, Scheiflinger F, Kerschbaumer R (2015). "Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients". Therapeutic Agents: Biological. Vol. 14. pp. A153. doi:10.1158/1535-7163.TARG-15-A153. {{cite book}}: |journal= ignored (help)
  2. ^ a b Clinical trial number NCT02448810 for "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT01765790 for "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumor" at ClinicalTrials.gov
  4. ^ a b "Imalumab". AdisInsight. Springer Nature Switzerland AG.